Login
Novo Nordisk NYSE: NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
| Name | Novo Nordisk |
| Ticker | NVO |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 69.44 |
| 52W Low/High | 49.46 / 69.57 |
| Market cap | 164 B |
| 1Y Total Return |
33.63%
Strong |
| 1Y Volatility |
29.78%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
Details
| Ticker | NVO |
| Name | Novo Nordisk |
| ISIN | US6701002056 |
| CUSIP | |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Diabetes |
| Country | Denmark |
| Currency | U.S. Dollar |
Share as of 9/18/20
| Close Price | 69.44 |
| 52W Low/High | 49.46 / 69.57 |
| Market cap | 164 B |
| 1Y Total Return |
33.63%
Strong |
| 1Y Volatility |
29.78%
Low Risk |
| Beta | 0.45 |
| PE (trailing) |
26.16
Average |
| 12M Dividends | 0.186858 |
| Last Dividend Date | 8/14/20 |
| Dividend Yield | 0.27% |
Fin. Strength
| Net Profit Margin | 32.7% |
| Cash from Op. / Cur. Liabilities | 0.83 |
| Diluted Earnings / Share | 2.65 |
| ROE | 73.4% |
| ROIC | 100.9% |
| Price / Revenue | - |
| Price / Book | - |
| Price / CF | - |
| Current Ratio | 1.1 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.07 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
19,120
|
21,939
|
17,571
|
17,569
|
16,469
|
-
|
|
| Gross Profit |
15,998
|
18,428
|
14,745
|
14,867
|
13,971
|
-
|
|
| R&D |
2,274
|
2,568
|
2,246
|
2,251
|
2,083
|
-
|
|
| EBITDA |
9,187
|
10,367
|
8,493
|
8,397
|
7,618
|
-
|
|
| Operating Income |
8,298
|
9,689
|
7,539
|
7,770
|
6,796
|
-
|
|
| Net Income exc. Extra |
6,259
|
7,210
|
6,309
|
5,940
|
5,383
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
| EPS exc. Extra |
2.65
|
3.01
|
2.58
|
2.37
|
2.11
|
-
|
|
| Dividend |
0.19
|
0.15
|
0.20
|
0.14
|
0.14
|
0.08
|
|
| Div. Yield (an.) |
1.89%
|
2.01%
|
2.72%
|
2.15%
|
1.79%
|
0.96%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
20,562
|
17,704
|
-
|
15,050
|
13,174
|
11,958
|
|
| Cash, Eq & Invt ShortTerm |
3,757
|
2,171
|
-
|
3,282
|
2,272
|
1,741
|
|
| Total Current Assets |
11,115
|
8,817
|
-
|
9,073
|
7,855
|
6,961
|
|
| Total Non-Current Assets |
9,447
|
8,887
|
-
|
5,977
|
5,320
|
4,996
|
|
| Intangibles |
874
|
886
|
-
|
407
|
315
|
215
|
|
| Total Liabilities |
11,490
|
9,733
|
-
|
7,598
|
6,819
|
6,206
|
|
| Total Current Liabilities |
10,164
|
8,498
|
-
|
6,742
|
6,198
|
5,675
|
|
| Long Term Debt |
1,327
|
1,236
|
-
|
856
|
620
|
531
|
|
| Shareholder equity |
9,072
|
7,971
|
-
|
7,452
|
6,356
|
5,752
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
8,478
|
6,601
|
7,184
|
7,470
|
6,594
|
-
|
|
| Depreciation |
867
|
690
|
502
|
527
|
446
|
-
|
|
| Cash from Investing |
-1,378
|
-1,925
|
-1,657
|
-1,050
|
-1,400
|
-
|
|
| Capex |
1,064
|
1,495
|
1,439
|
1,144
|
926
|
-
|
|
| Cash from Financing |
-5,499
|
-5,290
|
-5,774
|
-5,346
|
-4,930
|
-
|
|
| Stock Issued |
-2,419
|
-2,304
|
-2,676
|
-2,415
|
-2,507
|
-
|
|
| Debt (LT) Issued |
-111
|
-51
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
6,275
|
-
|
-
|
4,336
|
4,665
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
32.7%
|
32.9%
|
35.9%
|
33.8%
|
32.7%
|
-
|
|
| NCFO / Op.Income |
102.2%
|
68.1%
|
95.3%
|
96.1%
|
97.0%
|
-
|
|
| Current Ratio |
1.1
|
1.0
|
-
|
1.3
|
1.3
|
1.2
|
|
| Financial Leverage D/E |
0.07
|
0.08
|
-
|
0.03
|
0.01
|
0.02
|
|
| Return on Capital Avg |
100.9%
|
212.2%
|
249.6%
|
119.9%
|
115.6%
|
-
|
|
| Return on Shareholder Equity |
73.4%
|
-
|
-
|
86.0%
|
88.3%
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available